Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Pfizer    PFE

Mes dernières consult.
Most popular
Analysis summary4-Traders Strategies

David Meurisse

Contributor / Partner
share with twitter share with LinkedIn share with facebook
share via e-mail

Back on a long term support level

Strategy published on 10/14/2016 | 11:10
long trade
Stop-loss triggered
Entry price : 32.825$ | Target : 36.9$ | Stop-loss : 31.9$ | Potential : 12.41%
Pfizer Inc. shares have returned to important technical levels around 32.71 USD based on weekly price data. The timing seems attractive to be a buyer of this stock.
Investors have an opportunity to buy the stock and target the $ 36.9.
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.

  • The share is getting closer to its long-term support in weekly data, at USD 32.71, which offers good timing for buyers.
  • Share prices are approaching a strong support area in daily data, which offers good timing for investors.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Historically, the company has been releasing figures that are above expectations.
  • This company will be of major interest to investors in search of a high dividend stock.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • The tendency within the weekly time frame is positive above the technical support level at 32.71 USD

  • The company's enterprise value to sales, at 4.22 times its current sales, is high.
share with twitter share with LinkedIn share with facebook
share via e-mail

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials ($)
Sales 2018 54 461 M
EBIT 2018 20 838 M
Net income 2018 12 806 M
Debt 2018 27 450 M
Yield 2018 3,74%
P/E ratio 2018 16,76
P/E ratio 2019 15,49
EV / Sales 2018 4,52x
EV / Sales 2019 4,23x
Capitalization 219 B
Surperformance© ratings
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Earnings quality
Business Predictability
P/E ratio
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
Bollinger Spread
Unusual Volumes
Duration : Period : Day
Pfizer Technical Analysis Chart | PFE | US7170811035 | 4-Traders
Duration : Period : Week
Pfizer Technical Analysis Chart | PFE | US7170811035 | 4-Traders